

PRESS CLIPPING SHEET

PUBLICATION:	Identity
DATE:	September-2018
COUNTRY:	Egypt
CIRCULATION:	15,000
TITLE :	Novartis S.A.E announces FDA approval for Deferasirox for easier treatment administration for patients with Thalassemia (Chronic Iron Overload).
PAGE:	63
ARTICLE TYPE:	Agency-Generated News
REPORTER:	Staff Report
AVE:	1,500



Novartis S.A.E announces FDA approval for Deferasirox for easier treatment administration for patients with Thalassemia (Chronic Iron Overload)

Novartis today, in a joint press conference with the Egyptian Thalassemia Association (ETA), announced the launch of its first to market drug, Deferasirox film coated tablets, a new oral formulation for oral suspension taken once daily for the treatment of chronic iron overload; a disease that affects 5-9% of Egyptians